Inhibitors of NF-kappaB signaling: 785 and counting

Area of Science:

• Molecular Biology
• Immunology
• Pharmacology

Background:

• Nuclear factor kappa B (NF-kappaB) transcription factors are crucial regulators of inflammation, immune responses, cell growth, and apoptosis.
• The NF-kappaB signaling pathway is frequently dysregulated in chronic inflammatory diseases and cancer, making it a significant therapeutic target.
• Understanding the molecular intricacies of the NF-kappaB pathway is essential for developing effective modulators.

Purpose of the Study:

• To review the landscape of identified inhibitors targeting the NF-kappaB signaling pathway.
• To categorize the diverse range of molecules that modulate NF-kappaB activity.
• To discuss the therapeutic potential of NF-kappaB inhibitors in various diseases.

Main Methods:

• Comprehensive literature review of identified NF-kappaB pathway inhibitors.
• Classification of inhibitors based on their chemical nature (natural/synthetic) and mechanism of action.
• Analysis of the potential applications of these inhibitors in disease treatment.

Main Results:

• Over 750 inhibitors of the NF-kappaB pathway have been identified.
• Inhibitors encompass a wide array of compounds, including antioxidants, peptides, small RNA/DNA, microbial/viral proteins, small molecules, and engineered polypeptides.
• These inhibitors act at various levels, with some broadly inhibiting NF-kappaB induction and others targeting specific pathways or multiple steps.

Conclusions:

• NF-kappaB pathway inhibitors represent a promising class of therapeutic agents for cancers, neurodegenerative, and inflammatory diseases.
• While currently not in clinical use, specific NF-kappaB inhibitors are anticipated for future therapeutic development.
• The therapeutic benefits of many natural products may be attributed to their NF-kappaB inhibitory properties.